開拓藥業有限公司 *

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

VOLUNTARY ANNOUNCEMENT

COMPLETION OF FIRST SUBJECT ENROLLMENT IN PHASE III STAGE PIVOTAL CLINICAL TRIAL OF KX-826 TINCTURE 1.0% FOR THE TREATMENT OF MALE ADULT AGA IN CHINA

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") to update its shareholders and potential investors on the latest developments related to the Group.

Reference is made to the voluntary announcement of the Company dated 16 October 2024, in relation to the pivotal clinical trial (the "**Pivotal Clinical Trial**") of KX-826 tincture 1.0% for the treatment of male adult androgenetic alopecia ("**AGA**") in China, the first subject enrollment of the phase II stage of which was completed on 15 October 2024.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the Company has successfully completed the first subject enrollment recently in the phase III stage (the "**Phase III Stage**") pivotal clinical trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of male adult AGA in China.

The Pivotal Clinical Trial is a multi-center, randomized, double-blind, vehicle controlled phase II/III study with adaptive designs to evaluate the efficacy and safety of KX-826 tincture 1.0% for the topical treatment of male adults with AGA in China. The Pivotal Clinical Trial adopts a phase II/III operational seamless design, namely 2-in-1 design, with Professor Jianzhong Zhang (張建中) and Professor Cheng Zhou (周城) from Peking University People's Hospital as the lead principal investigator. The Phase III Stage is expected to involve 25 clinical research centers in China and enroll 666 patients within 5

months. The patients will receive treatment with the stipulated dosages over a period of 24 weeks, followed by a 1-month safety observation. The Phase III Stage is expected to be completed by the end of 2025.

The Company's preclinical studies have shown that KX-826 tincture 1.0% has significantly increased the retention concentration of the tincture on human scalp cells compared to KX-826 tincture 0.5% used in the previous phase III clinical trial, and is expected to enhance the clinical efficacy. The clinical trial of KX-826 tincture 1.0% is expected to maintain excellent safety profile and present superior efficacy compared to KX-826 tincture 0.5%.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: Apart from the cosmetic product of 826 topical anti-hair loss solution, there is no assurance that other products of KX-826 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, 30 December 2024

As at the date of this announcement, the executive Directors are Dr. Youzhi Tong and Dr. Xiang Ni; the non-executive Directors are Mr. Weipeng Gao and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*